Article
Primary resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in patients with non-small-cell lung cancer harboring TKI-sensitive EGFR mutations: an exploratory study.
Annals of oncology : official journal of the European Society for Medical Oncology - 1 Aug 2013
Lee J K, Shin J-Y, Kim S, Lee S, Park C, Kim J-Y, Koh Y, Keam B, Min H S, Kim T M, Jeon Y-K, Kim D-W, Chung D H, Heo D S, Lee S-H, Kim J-I
Abstract excerpt
BACKGROUND: The mechanism of primary resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in EGFR-mutant non-small-cell lung cancer (NSCLC) has not been clearly understood. PATIENTS AND METHODS: Eleven patients exhibiting primary resistance (disease progression <3 months) were identified among 197 consecutive NSCLC patients with TKI-sensitive EGFR mutations who received EGFR...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.